• Biopsy Devices Market Viewed As A Stepping Stone Towards A World Of Minimally Invasive Healthcare Diagnosis – MarketIntelReports

    by on March 26th, 2017

    Wilmington, Delaware, United States, March 26, 2017 (GLOBE NEWSWIRE) — The report “World Biopsy Devices Market – Opportunities and Forecasts 2022”, available on MarketIntelReports, estimates that the market will grow at a healthy CAGR of 5.5% till 2022. 

    Browse 32 Market Tables as well as 50 Figures which are spread through 158 Pages and an in-depth TOC on the “Biopsy Devices Market Forecast 2022http://www.marketintelreports.com/report/allied0004/world-biopsy-devices-market–opportunities-and-forecasts-2014–2022

    Scope & Regional Forecast of the Biopsy Devices Market

    Biopsy Devices Market was valued at $1,621 million, and is expected to reach $2,399 million by 2022, supported by a CAGR of 5.5%. Biopsy is the surgical removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions. This diagnostic procedure is generally performed by surgeons, radiologists, and interventional cardiologists, to confirm the presence of cancerous tissue. Biopsy procedures can be performed for almost any organ with the help of a specific biopsy device. Conventional biopsy devices can be complemented with advanced imaging technologies such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others to perform a biopsy procedure with accuracy and minimal invasiveness. These integrated procedures are important to perform biopsies in critical areas of the body such as the lungs, liver, and kidney.

    Request Sample PDF Brochure @ http://www.marketintelreports.com/pdfdownload.php?id=allied0004

    Increasing incidences of cancer such as breast, prostate, & lung, and rapid technological advancements have been stimulating the growth of the biopsy devices market. Moreover, increase in awareness for the diagnosis of chronic diseases such as breast cancer and lung cancer is also increasing the demand for integrated biopsy technologies such as MRI-guided biopsy. On the contrary, the use of advanced biopsy devices in developing countries is still restricted due to high cost, unawareness for the diagnosis of chronic diseases, and lack of technical expertise. However, companies are now concentrating on developing cost-effective biopsy devices, which would decrease the overall cost of biopsy procedures.

    Inquiry before buying report @ http://www.marketintelreports.com/inquiry-before-buying.php?id=allied0004

    Prominent Segmentations Involved in the Biopsy Devices Market

    The Biopsy Devices Market can be broken down into various segmentations on the basis of –

    • Type: Breast Biopsy Devices, Gastro Intestinal Biopsy Devices, Soft Tissue Biopsy Devices, Bronchial Biopsy Devices, Gynaecological Biopsy Devices, Robotic Guidance Systems and Others.
    • Application: Breast Biopsy, Gastroenterology Biopsy, Prostate Biopsy, Liver biopsy, Lung biopsy, Kidney Biopsy, Gynaecological Biopsy and Others.
    • Technology: MRIguided biopsy,  StereotacticGuided Breast Biopsy, UltrasoundGuided Biopsy,  CT guided biopsy and Others (positron emission mammography (PEM) imaging technology, Xray technology and RX technology).
    • End Users: Diagnostic Centers and Hospitals.
    • Geographical Location: North America, Europe, Asia-Pacific and LAMEA.

    Some of the sample companies profiled in the Biopsy Devices Market report are as follows:

    • Leica Biosystems (Devicor Medical products, inc.)
    • Boston Scientific Corporation
    • Cook Medical, Inc.
    • Hologic, Inc.
    • Mauna kea technologies.
    • Becton Dickinson and Company (Carefusion Corp.)
    • C. R. BARD, INC.
    • Fujifilm Holdings Corp.

     Why buy this report?

    • Get a detailed picture of the Biopsy Devices Market.
    • Pinpoint growth sectors and identify factors driving change.
    • Understand the competitive environment, the market’s major players and leading brands.
    • A five-year forecast method is used in order to assess how the market is predicted to develop.

    Purchase Biopsy Devices Market Report @ http://www.marketintelreports.com/purchase.php?id=allied0004

    About Us:

    MarketIntelReports (MIR) aims to empower our clients to successfully manage and outperform in their business decisions. We do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers. 

    MarketIntelReports currently has more than 150,000 plus titles and 100+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

    Media Contact:

    Company Name: Market Intel Reports
    Contact Person: Mayur S
    Email: sales@marketintelreports.com  
    Phone: 1-302-261-5343
    Address: 2712 Centerville Road, Suite 400
    City: Wilmington
    State: Delaware
    Country: United States

  • Art Attack 2016 Winner

    Art Attack by on March 24th, 2017

    We know this industry is filled with creative people and artists who use their talents for more than just marketing campaigns. That is why five years ago we started our now annual cover competition in which we ask for original artwork created by people within this industry. Last year, we received more than 300 submissions, […]

  • VIDEO: Looking at keloids from a different perspective

    by on March 24th, 2017

    AT AAD 17 ORLANDO (FRONTLINE MEDICAL NEWS) – It may be time to start considering new options for treating keloids, according to Amy McMichael, MD, professor of dermatology at Wake Forest University, Winston-Salem, N.C. At the annual meeting of the American Academy of Dermatology, Dr. McMichael discussed one of the highlights of the annual symposium […]

  • PM360 Presents The 2017 Greatest Creators

    Showcase by on March 24th, 2017

    PM360’s annual showcase of some of the best creative work from agencies serving the life science industry from the past year. Here are our 16 selections of the best submissions we received this year. Each agency explains the creative process behind their campaign and lists the people responsible for working on it. AbelsonTaylor ARK Media […]

  • Grandparents aid in early diagnosis of autism

    by on March 24th, 2017

    Family members other than parents can play a key role in initial recognition of problems prior to diagnosis of autism, which may lead to earlier diagnosis and potentially better outcomes, a study found. Of 477 parents of children with autism who were surveyed online, 25% of parents reported that other individuals indicated their child might […]

  • FDA approves first treatment for metastatic Merkel cell carcinoma

    by on March 24th, 2017

    The Food and Drug Administration has granted accelerated approval to avelumab for the treatment of metastatic Merkel cell carcinoma (MCC) in adult and pediatric patients aged 12 years and older. Avelumab, a programmed death-ligand 1 (PD-L1)–blocking human IgG1 lambda monoclonal antibody, is the first FDA-approved treatment for metastatic MCC. Approval was based on a 33% […]

  • Digoxin definitively dissed for AF

    by on March 24th, 2017

    AT ACC 17 WASHINGTON (FRONTLINE MEDICAL NEWS) – In what could prove to be the final word in the clinical controversy over the safety of prescribing digoxin in patients with atrial fibrillation, a secondary analysis of the roughly 18,000-patient ARISTOTLE trial has come down emphatically on the side of avoiding the venerable drug. “The clinical […]

  • CDC reports two new Zika-related pregnancy losses

    by on March 24th, 2017

    The first pregnancy losses with Zika-related birth defects since last summer were reported March 14 by the Centers for Disease Control and Prevention. Two new cases were reported to the U.S. Zika Pregnancy Registry between Feb. 21 and March 14 – the time period covered by the most recent release of data from the CDC. […]

  • Preoperative opioid use linked to worse outcomes following abdominal surgery

    by on March 24th, 2017

    FROM THE ANNALS OF SURGERY Surgeons need to do more to identify patients who are taking opioids preoperatively, because this is a population that appears to be at a higher risk of worse surgical outcomes, according to a large retrospective investigation. “Opioid users represent a potentially high-risk surgical population and may require tailored perioperative care […]

  • Parental perception of asthma may predict future acute visits

    by on March 24th, 2017

    AT THE 2017 AAAAI ANNUAL MEETING ATLANTA (FRONTLINE MEDICAL NEWS) – For low-income and minority children with asthma, parents’ perception of a child’s asthma control may be an important predictor of future acute visits, independent of guideline-based criteria for asthma control, judging from the results from a prospective cohort study. The National Asthma Education and […]

  • Lonely in the middle

    by on March 24th, 2017

    Those of us who consider ourselves centrists are feeling pretty lonely right now. It seems everyone else, or at least all of the folks in Washington, have fled to the extreme political poles and left us to search for a patch of middle ground to stand on. It appears that without courageous leadership the silent […]

  • Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine

    by on March 24th, 2017

    NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the publication of previously-reported results from the Phase 2 study of 1404 in the online edition of the Journal of Nuclear Medicine.  1404 is a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer.

    The data published today reviews previously reported data demonstrating the sensitivity of 1404 to detect prostate cancer using both visual and semi-quantitative tumor to background (TBR) scores.  The uptake within the prostate gland evaluated by both visual and TBR scores correlated significantly with Gleason Score.

    “The results from this study highlight the potential for 1404 to better assess the stage and extent of a patient’s prostate cancer versus biopsy,” stated Professor Karolien Goffin, M.D., Ph.D., University Hospitals Leuven, author of the publication. “Importantly, 1404 may be used as a surrogate marker for Gleason Score, and could be used to evaluate lymph node involvement in patients with intermediate and high risk prostate cancer, which signals disease that has spread beyond the prostate.  The data provide a strong rationale for continued development of 1404.”

    Progenics is currently evaluating 1404 in a Phase 3 study.  The study is enrolling patients with newly diagnosed low grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and/or are candidates for active surveillance. The study is designed to evaluate the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.

    About 1404, an Imaging Compound Targeting Prostate Specific Membrane Antigen

    Progenics’ molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of > 95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with Technetium-99m, a gamma-emitting isotope that is widely available, is easy to prepare, and is attractive for nuclear medicine imaging applications. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.

    About Prostate Cancer

    Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in seven men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that each year approximately 161,360 new cases of prostate cancer will be diagnosed and about 26,730 men will die of the disease. Approximately 2.9 million men in the U.S. currently count themselves among prostate cancer survivors.

    About Progenics

    Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.

    This press release may contain projections and other “forward-looking statements” regarding future events. Statements contained in this communication that refer to Progenics’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics’ current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

    Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company’s SEC filings.

    (PGNX-F)

    CONTACT: Contact:
    
    Melissa Downs
    Investor Relations
    (646) 975-2533
    mdowns@progenics.com
  • Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine

    by on March 24th, 2017

    NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the publication of previously-reported results from the Phase 2 study of 1404 in the online edition of the Journal of Nuclear Medicine.  1404 is a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer.

    The data published today reviews previously reported data demonstrating the sensitivity of 1404 to detect prostate cancer using both visual and semi-quantitative tumor to background (TBR) scores.  The uptake within the prostate gland evaluated by both visual and TBR scores correlated significantly with Gleason Score.

    “The results from this study highlight the potential for 1404 to better assess the stage and extent of a patient’s prostate cancer versus biopsy,” stated Professor Karolien Goffin, M.D., Ph.D., University Hospitals Leuven, author of the publication. “Importantly, 1404 may be used as a surrogate marker for Gleason Score, and could be used to evaluate lymph node involvement in patients with intermediate and high risk prostate cancer, which signals disease that has spread beyond the prostate.  The data provide a strong rationale for continued development of 1404.”

    Progenics is currently evaluating 1404 in a Phase 3 study.  The study is enrolling patients with newly diagnosed low grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and/or are candidates for active surveillance. The study is designed to evaluate the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.

    About 1404, an Imaging Compound Targeting Prostate Specific Membrane Antigen

    Progenics’ molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of > 95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with Technetium-99m, a gamma-emitting isotope that is widely available, is easy to prepare, and is attractive for nuclear medicine imaging applications. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.

    About Prostate Cancer

    Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in seven men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that each year approximately 161,360 new cases of prostate cancer will be diagnosed and about 26,730 men will die of the disease. Approximately 2.9 million men in the U.S. currently count themselves among prostate cancer survivors.

    About Progenics

    Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.

    This press release may contain projections and other “forward-looking statements” regarding future events. Statements contained in this communication that refer to Progenics’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics’ current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

    Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company’s SEC filings.

    (PGNX-F)

    CONTACT: Contact:
    
    Melissa Downs
    Investor Relations
    (646) 975-2533
    mdowns@progenics.com
Back to top